Literature DB >> 9210605

Present status of autoimmune hepatitis in Japan--correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis.

G Toda1, M Zeniya, F Watanabe, M Imawari, K Kiyosawa, M Nishioka, T Tsuji, M Omata.   

Abstract

BACKGROUND/AIMS: A nationwide survey of autoimmune hepatitis (AIH) was carried out in Japan.
METHODS: Four hundred and ninety-six patients were enrolled by questionnaires sent to 101 hospitals with hepatology specialists.
RESULTS: The clinical features of Japanese AIH were as follows: most patients were middle-aged women; serum autoantibodies, especially antinuclear antibody, were frequently positive, serum IgG level was high, and HLA-DR4 was the major HLA allotype. Liver-kidney microsomal type 1 antibody was positive in nine of 79 patients tested. Eight of these antibody positive patients were also positive for antinuclear antibody and five for anti-smooth muscle antibody. Ninety-two percent of the patients showed piecemeal necrosis and 60% bridging necrosis; plasma cell infiltration in the portal areas was observed in 50% of the patients. Only 12.3% were diagnosed as having liver cirrhosis. A favorable effect of corticosteroid, normalization of serum transaminases, was observed in 89% of 317 patients, who were treated with an initial dose of over 30 mg/day. Sixty-two patients were positive for hepatitis C virus (HCV) markers. In these patients, however, only one patient was liver-kidney microsomal type 1 antibody positive. Corticosteroid was effective in 30 (81%) of 37 HCV-marker-positive patients treated with this agent. Thus the efficacy of corticosteroid did not differ from that in AIH patients without HCV infection (90%). Similarly, interferon treatment was used in 20 patients, all of whom were positive for HCV-RNA, and resulted in 50% efficacy as determined by normalization of the serum transaminase level 6 months after treatment. The International Diagnostic Scoring System for the diagnosis of AIH worked well in these patients, except for HCV-infected individuals, that is, approximately 10% of the total of AIH patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210605     DOI: 10.1016/s0168-8278(97)80453-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  35 in total

1.  Autoimmune Hepatitis in Hawai'i.

Authors:  Tanner I Kim; Jaclyn E Kagihara; Naoky C S Tsai; Marina M Roytman
Journal:  Hawaii J Med Public Health       Date:  2015-08

2.  Is the new diagnostic scoring system of Zeniya and colleagues useful for autoimmune liver diseases?

Authors:  Norio Horiike; Morikazu Onji
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model.

Authors:  Mikio Zeniya; Fumitoki Watanabe; Toshio Morizane; Minoru Shibata; Shiro Maeyama; Masayoshi Kage; Yasuni Nakanuma; Gotaro Toda
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

4.  Successful treatment with corticosteroid and lamivudine for autoimmune hepatitis in a patient with asymptomatic HBV infection.

Authors:  Reiichiro Kuwahara; Hiroki Saitsu; Mitsuhiko Abe; Akio Takata; Kazuo Tanaka; Teruko Hino; Tatsuya Ide; Ryoko Kuromatsu; Ken Tanikawa; Masayoshi Kage; Ryukichi Kumashiro; Michio Sata
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

5.  Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community.

Authors:  Henry V Chung; Mark Riley; Jin K Ho; Benjamin Leung; Gareth P Jevon; Laura T Arbour; Colin Barker; Richard Schreiber; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2007-09       Impact factor: 3.522

6.  Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population.

Authors:  Junichi Kubota; Fusao Ikeda; Ryo Terada; Haruhiko Kobashi; Shin-ichi Fujioka; Ryoichi Okamoto; Shinsuke Baba; Youichi Morimoto; Masaharu Ando; Yasuhiro Makino; Hideaki Taniguchi; Tetsuya Yasunaka; Yasuhiro Miyake; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2009-06-27       Impact factor: 7.527

7.  Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis.

Authors:  Yasuhiro Miyake; Yoshiaki Iwasaki; Haruhiko Kobashi; Tetsuya Yasunaka; Fusao Ikeda; Akinobu Takaki; Ryoichi Okamoto; Kouichi Takaguchi; Hiroshi Ikeda; Yasuhiro Makino; Masaharu Ando; Kohsaku Sakaguchi; Kazuhide Yamamoto
Journal:  Hepatol Int       Date:  2009-10-22       Impact factor: 6.047

8.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

9.  An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.

Authors:  Akiko Hisamochi; Masayoshi Kage; Tatsuya Ide; Teruko Arinaga-Hino; Keisuke Amano; Reiichiro Kuwahara; Kei Ogata; Ichiro Miyajima; Ryukichi Kumashiro; Michio Sata; Takuji Torimura
Journal:  J Gastroenterol       Date:  2015-10-30       Impact factor: 7.527

10.  Long-term treatment outcomes for autoimmune hepatitis in Korea.

Authors:  Jae Sook Kil; Joon Hyoek Lee; A-Reum Han; Ja Young Kang; Hye Jin Won; Han Young Jung; Hyun Min Lim; Geum-Youn Gwak; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.